Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Latest News
26
Jan2024
January 26, 2024
26
Jan2024
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
January 26, 2024
19
Jan2024
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
January 19, 2024
19
Jan2024
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
January 19, 2024
19
Jan2024
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
January 19, 2024
17
Nov2023
Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)
November 17, 2023
17
Nov2023
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECTÂ
November 17, 2023
16
Nov2023
A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
November 16, 2023
02
Nov2023
Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)
November 2, 2023
14
Oct2023
Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database
October 14, 2023